Elizabeth Daglish, MS
Director, Regulatory Strategy

Elizabeth Daglish is a Director of Regulatory Strategy at Advyzom and operates out of the Boston area. She is responsible for providing companies with strategic regulatory guidance and acts as a regulatory lead on programs. Elizabeth has recently filed and successfully obtained US and EU approval for an anti-infective product for resistant pathogens. She also has experience across therapeutic areas including immunotherapies, cardiovascular, and anti-infectives. Elizabeth has in depth global regulatory experience, and provides global regulatory strategy and leadership of US and EU submissions on development programs from early development thru marketing authorizations. Elizabeth has led global regulatory strategy for NDA/MAA filings and post-approval supplements/variations to successful approvals. She also leads strategic interactions with Health Authorities throughout development and has strong expertise in preparation and submission of regulatory documents to support clinical trial initiation (IND/CTA submissions) and responses to health authority requests. Elizabeth also has experience in the development of global pediatric plans (PSP and PIP), Orphan designation requests in US and EU, and QIDP designation.

Elizabeth has 15 years of experience in the pharmaceutical industry. Prior to joining Advyzom, Elizabeth was an independent Regulatory Affairs Consultant. Previously, she was a Regulatory Affairs Consultant for ICON plc.. Her responsibilities as a consultant have included serving as the Acting Head of Regulatory for a small biotech company and managing a wide variety of development and registration submissions and health authority interactions for both large and small companies. She has led the regulatory activities for products through development to filing and successful approval. Elizabeth has also led teams through many Health Authority interactions. Earlier in her career, Elizabeth worked for Abbott Diabetes Care as a Senior Project Manager responsible for the global registration of new products.

Elizabeth has a Master of Science degree in Medical Toxicology from Cardiff University, United Kingdom and a Bachelor of Science in Sports Science from the University of Richmond. She is a Member of The Organization for Professionals in Regulatory Affairs (TOPRA).